Ubs Oconnor LLC Amylyx Pharmaceuticals, Inc. Transaction History
Ubs Oconnor LLC
- $1.46 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding AMLX
# of Institutions
127Shares Held
44.4MCall Options Held
235KPut Options Held
530K-
Tcg Crossover Management, LLC Palo Alto, CA4.64MShares$24.6 Million1.95% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.09MShares$16.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.67MShares$14.1 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY2.13MShares$11.2 Million0.18% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL2.02MShares$10.7 Million0.04% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $310M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...